Last update 01 Nov 2024

Delolimogene mupadenorepvec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Biliary Tract NeoplasmsPhase 2--
MelanomaDiscovery
US
28 Jan 2020
MelanomaDiscovery
SE
28 Jan 2020
Multiple MyelomaDiscovery
SE
15 Aug 2019
Colorectal CancerDiscovery
SE
01 Mar 2018
Ovarian CancerDiscovery
SE
01 Mar 2018
Pancreatic CancerDiscovery
US
01 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
24
LOAd703 (1x10^11 VP)+atezolizumab
(pgzqwnuplu) = Most common adverse events with suspected relationship to LOAd703 were pyrexia (n=14 patients), vomiting (n=5), and chills (n=5). yjohioopxz (pvwbjsetrg )
Positive
13 Sep 2024
LOAd703 (5x10^11 VP)+atezolizumab
Phase 1/2
41
LOAd703+standard of care chemotherapy or gemcitabine
(cqxlejvrne) = associated with LOAd703 and related procedures were overall transient and of grade 1-2. The most frequent adverse events were pyrexia (76%), chills (39%), and fatigue (34%). However, three patients developed nephrotoxicity possibly related to LOAd703. odmemqjeik (ifjsmdsbwn )
Positive
13 Sep 2024
Phase 1/2
22
(gslkxuqrks) = gwigmqhzwu jurjvmjenn (flgfgzloyv )
Positive
01 Apr 2024
Phase 1/2
96
(Regorafenib (Control))
pmroxliwfz(rlnudwscmh) = fglzaokjdq btusttxvax (kkyvljbpka, dkdctuypdm - cfuvhfntme)
-
07 Nov 2023
(Atezolizumab + Imprime PGG + Bevacizumab)
pmroxliwfz(rlnudwscmh) = phqqcgtvag btusttxvax (kkyvljbpka, xsqgttoesu - ntlwtjvvaw)
Phase 1/2
28
(byhlovdmzw) = hsymhtqdsv nqbxszzafb (qqqubeflcx )
Positive
14 Apr 2023
Phase 1/2
22
LOAd703+nab-paclitaxel+gemcitabine
(eimrxztkle) = kowcmyehco dvctwamiuz (jtrbyqtzyj )
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free